SCHEMBL24370197

SCHEMBL24370197

CC(C)c1cnn2ccc(Cl)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHB3 P54753 3/20 0.41
HTR2A P28223 2/20 0.36
HTR2C P28335 2/20 0.36
PIK3CD O00329 2/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CB P42338 2/20 0.35
KMO O15229 3/20 0.35
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
KCNH2 Q12809 1/20 0.33
PTGER1 P34995 1/20 0.32
FABP4 P15090 1/20 0.32
PDE5A O76074 1/20 0.31
PDE9A O76083 1/20 0.31
DRD4 P21917 1/20 0.31
DRD3 P35462 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
HTT P42858 1/20 0.31
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25802396 0.81 EPHB3 (0.40) EPHB3HTR2AHTR2CPIK3CDPIK3CA
SCHEMBL26596835 0.81 FYN (0.32) PIK3CDPIK3CAPIK3CB
SCHEMBL26196160 0.79 PIK3CA (0.37) HTR2AHTR2CPIK3CDPIK3CAPIK3CB
SCHEMBL24013121 0.79 HTR2B (0.41) HTR2AHTR2CPIK3CDPIK3CAPIK3CB
SCHEMBL26661950 0.78 HTR2C (0.44) EPHB3HTR2AHTR2CPIK3CALMNA
SCHEMBL19631426 0.77 PIK3CA (0.31) PIK3CDPIK3CAPIK3CB
SCHEMBL24370193 0.77 EPHB3 (0.43) EPHB3PIK3CDPIK3CAPIK3CBKMO
SCHEMBL25099097 0.76 MAT2A (0.40) PIK3CDPIK3CAPIK3CBHSP90AA1HSP90AB1
SCHEMBL24370198 0.74 EPHB3 (0.40) EPHB3HTR2AHTR2CKMOGABRA1
SCHEMBL20356834 0.74 PIK3CD (0.31) PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339980-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-10-26 US disclosed
WO-2023205475-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2023-10-26 WO disclosed
WO-2023164237-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 WO disclosed
WO-2022087634-A1 CTPS1 INHIBITORS AND USES THEREOF NIMBUS CLOTHO, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339980-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 EPHB3 3578/4885HTR2A 1684/4885HTR2C 2699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.